Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response

ADKINS, I., SADÍLKOVÁ, I., HRADILOVÁ, N., TOMALA, Jakub, TOMALOVÁ, Barbora, KOVÁŘ, Marek, MIKYSKOVÁ, R., REINIŠ, Milan, DE MARTYNOFF, G., BECHARD, D., MOEBIUS, U., SPÍŠEK, R. Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response. Cancer Research. 2018, 78(13 S). ISSN 0008-5472. E-ISSN 1538-7445. Available: doi: 10.1158/1538-7445.AM2018-3775